Sight Sciences, Inc. · NASDAQ:SGHT
Sight Sciences — Q3 2026 Earnings Presentation
29 slides from Sight Sciences's earnings presentation, Nov 4, 2026
Slide 1: Investor Presentation November 2026
Investor Presentation November 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act o
Slide 3: Make early intervention the new standard of care in eye care
| 3 We aim to make early intervention the new standard of care in eye care
Slide 4: Two growing franchises, one mission: early intervention
Two growing franchises, one mission: early intervention | 4 01 Interventional Glaucoma 4M+ Diagnosed glaucoma patients (IG)37 OMNI comprehensively treats the conventional outflow pathway Market leader in implant free MIGS YTD revenue of $60.1M, up 7% Y/Y 02 Interventional Dry Eye 7M+ Diagnosed moder
Slide 5: Q3 Results: Revenue Growth of 25%, Cash usage improved by 74%
4 Q3 Results: Revenue Growth of 25%, Cash usage improved by 74% Q3 2026 REVENUE $24.9M +25% Y/Y Third consecutive quarter of double-digit revenue growth; Two growing segments; IDE scaling rapidly Investing for Growth While Reducing Cash Usage YTD Adj. OpEx at 99% of revenue (vs. 121% in PY) IG IDE +
Slide 6: IX: The Intersection of Intervention
INTERVENTIONAL GLAUCOMA (IG) INTERVENTIONAL DRY EYE (IDE) IX: The Intersection of Intervention Same practices, same patients. Many glaucoma patients have dry eye, and are seeking treatment for both conditions by the same eyecare provider A common interventional model. Procedural intervention vs dail
Slide 7: A strategic roadmap to transform eyecare for glaucoma and dry eye patients
A strategic roadmap to transform eyecare for glaucoma and dry eye patients by reducing patient burden, slowing disease progression, and improving outcomes. Embrace procedural intervention as a better alternative to medication management Intervene procedurally and address underlying disease over symp
Slide 8: Interventional Dry Eye
Interventional Dry Eye
Slide 9: MGD Affects Millions of People
MGD Affects Millions of People U.S. patients diagnosed with Dry Eye Disease (DED) 2 Million DED patients ~19 Up to 86% of DED is associated with poor tear quality due to Meibomian Gland Dysfunction (MGD ) 2, 3 Million MGD patients ~13 – 16 ~50% of DED patients have moderate to severe symptoms 2 (mos
Slide 10: A new order of care
A new order of care Effective intervention shouldn’t wait, because meibomian gland dropout is irreversible and critical to ocular surface health 4-6 TearCare targets the root cause of MGD: obstructed glands with demonstrated improvement of meibomian gland function 7 SAHARA Results: TearCare was clin
Slide 11: MGD is an Underserved Disease State
MGD is an Underserved Disease State The current market is dominated by eyedrops that do not address the underlying causes of MGD 10 Many dry eye treatments focus on increasing tear volume in aqueous deficient patients No interventional standard of care for treatment of MGD There is poor patient comp
Slide 12: TearCare Offers a Comprehensive Intervention for Evaporative Dry Eye Disease
TearCare Offers a Comprehensive Intervention Driving Leading Clinical Outcomes for Evaporative Dry Eye Disease Due to MGD OUR TECHNOLOGY: TEARCARE Comprehensive therapy to treat diseased meibomian glands Leading Clinical Trial Results: SAHARA, OLYMPIA >80K Procedures Performed 12
Slide 13: TearCare: The first and only MGD Treatment Indicated to Improve Meibomian Gland Function
TearCare: The first and only MGD Treatment Indicated to Improve Meibomian Gland Function Thin, wearable SmartLids® conform to the eyelid and allow natural blinking Precise, consistent, software- controlled thermal therapeutic melting cycle (at 45°C +/- 0.7°C for 15 minutes)13 Comprehensive gland cle
Slide 14: SAHARA: Randomized Controlled Trial comparing TearCare and Restasis
SAHARA: Randomized Controlled Trial comparing TearCare and Restasis®14 - Signs Superiority + Durability 15 - Head-to-Head Study TearCare vs Restasis 14 - Large Trial (N=345) - Randomized - Assessor Masked - 3 Stages - Long-term (2-year trial)
Slide 15: SAHARA RCT: TearCare Superior to Restasis in Tear Breakup Time
SAHARA RCT: Results TearCare Superior to Restasis in Tear Breakup Time Improvement 18 PHASE 1: TearCare Results at 6 Months Superior to Restasis 14, 16 in tear break-up time (TBUT) Non-inferior to Restasis in ocular surface disease index (OSDI) 17 Significant improvements in all signs and symptoms m
Slide 16: SAHARA RCT: 2 years of relief for the majority of patients
SAHARA RCT: Results 2 TearCare therapies in the first 5 months provided 2 years of relief for the majority of study patients19 PHASE 3: 24 Month Data All mean signs and symptoms remained statistically significantly better than study baseline at all time points measured through the end of study at 24
Slide 17: Interventional Dry Eye Scaling Commercially And Pursuing Expanded Market Access
Interventional Dry Eye Scaling Commercially And Pursuing Expanded Market Access With the power of TearCare, we can: Improve the lives of U.S. MGD patients Scale commercial resources with market access wins Target ~6,500 physicians identified as most likely to adopt MGD treatment procedures20 Activat
Slide 18: Interventional Glaucoma
Interventional Glaucoma ())
Slide 19: Glaucoma: Large + Underserved Market
Glaucoma - Leading cause of irreversible blindness22 - Predominantly managed with daily eye drops (compliance often poor)23 Normal Mild Moderate Severe Large + Underserved Market U.S. patients diagnosed with Glaucoma22 >4 MILLION
Slide 20: OMNI Surgical System Offers Leading Clinical Outcomes for POAG
OUR TECHNOLOGY: OMNI® SURGICAL SYSTEM OMNI Offers Leading Clinical Outcomes for Primary Open-Angle Glaucoma (POAG) Comprehensive treatment of diseased conventional outflow pathway Leading clinical trial and registry results: ROMEO, GEMINI, AAO IRIS® Registry >430K Procedures Performed 24
Slide 21: OMNI Comprehensively Treats the Conventional Outflow Pathway
OMNI Comprehensively Treats the Conventional Outflow Pathway Minimally Invasive + Efficacious A comprehensive procedure enabled by the OMNI® Surgical System to help restore natural outflow in the eye with up to 360° treatment of all three areas of resistance25 in the conventional outflow pathway
Slide 22: OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication
OMNI is Proven with Robust Clinical Evidence & Broad FDA Indication AGIS-7 Findings28 <18 mmHg is the target IOP to limit the progression of glaucoma. On average, there was zero change in visual field defect score for patients whose IOP stayed below 18 mmHg over 6 years. OMNI is the most comprehensi
Slide 23: Consistent Efficacy of OMNI in Combination Cataract and Standalone Trials
Consistent Efficacy of OMNI in Combination Cataract (CC) and Standalone (SA) Clinical Trials 29-32 COMBINATION CATARACT STANDALONE EFFICACY DEMONSTRATED OUT TO 3 YEARS GEMINI (12 Months)33 ROMEO Elevated IOP CC (24 Months) ROMEO Elevated IOP SA (24 Months) TREY SA (11 Months)33 GEMINI 2 IOP Outcomes
Slide 24: Large and Unmet Clinical Need for Standalone MIGS
Large and Unmet Clinical Need for Standalone MIGS Combination Cataract Standalone | 24 ~15% of POAG eyes34, ~90% of MIGS procedures34 Established, growing market Benefits from inherent IOP-lowering effect of cataract surgery Share-taking driven by efficacy, fast recovery times and attractive safety
Slide 25: MIGS for the Standalone Pseudophakic Patient: The Glaucoma Patient Journey
MIGS for the Standalone Pseudophakic Patient The Glaucoma Patient Journey35 36 Selective Laser Trabeculoplasty . Zone of unmet clinical need Pseudophakic POAG Patients 3-7 yrs post-op Glaucoma Diagnosis Patient diagnosed with glaucoma and begins their journey fighting the disease Topical Meds +/or S
Slide 26: Returning to High Growth in 2026
Returning to High Growth in 2026 Total Revenue Dry Eye Revenue Glaucoma Revenue +25% Q3 2026 Y/Y Revenue Growth FY26 Guidance Revenue $92M - $93M 39 +19% to 20% y/y Adj. OpEx 1 $92M - $94M 39 +5% to 7% y/y Historical financial results, including with respect to revenue and gross margin, may not be i
Slide 27: Sight Sciences
EZ S sight w™ Sciences’
Slide 28: References
References Adjusted operating expenses is a non-GAAP financial measure, which is calculated as operating expenses less stock-based compensation expense, depreciation and amortization, restructuring costs, and other one-time costs. For a reconciliation of adjusted operating expenses to operating expe
Slide 29: References
References 66% of TearCare® patients experienced dry eye relief for 2 years from study baseline. Study baseline refers to assessment at the start of SAHARA prior to any treatment and 5 months prior to the start of the Stage 3 durability stage. Months are measured from Study Baseline. Error bars are